Sintx Technologies, Inc. (NASDAQ:SINT) Sees Large Growth in Short Interest

Sintx Technologies, Inc. (NASDAQ:SINT) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 206,724 shares, an increase of 20.3% from the December 15th total of 171,790 shares. Based on an average daily trading volume, of 40,662 shares, the short-interest ratio is presently 5.1 days. Currently, 5.8% of the company’s shares are sold short. Currently, 5.8% of the company’s shares are sold short. Based on an average daily trading volume, of 40,662 shares, the short-interest ratio is presently 5.1 days.

Insiders Place Their Bets

In other Sintx Technologies news, CIO Gregg R. Honigblum purchased 8,200 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was purchased at an average cost of $4.26 per share, for a total transaction of $34,932.00. Following the transaction, the executive owned 201,067 shares in the company, valued at $856,545.42. The trade was a 4.25% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have purchased 83,200 shares of company stock worth $322,282. Insiders own 4.08% of the company’s stock.

Hedge Funds Weigh In On Sintx Technologies

Large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its position in Sintx Technologies by 33.5% in the 2nd quarter. Geode Capital Management LLC now owns 15,339 shares of the company’s stock valued at $49,000 after purchasing an additional 3,848 shares during the period. Veracity Capital LLC raised its holdings in Sintx Technologies by 10.3% during the third quarter. Veracity Capital LLC now owns 79,928 shares of the company’s stock worth $327,000 after buying an additional 7,464 shares during the last quarter. Finally, Virtus Wealth Solutions LLC bought a new position in shares of Sintx Technologies in the third quarter valued at $388,000. 18.38% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on SINT. Wall Street Zen lowered Sintx Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sintx Technologies in a research report on Wednesday, October 8th. Finally, Ascendiant Capital Markets lowered their price target on shares of Sintx Technologies from $25.00 to $16.00 and set a “buy” rating for the company in a report on Monday, December 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $16.00.

Sintx Technologies Trading Down 4.0%

Shares of NASDAQ SINT opened at $3.59 on Wednesday. The firm has a market capitalization of $13.21 million, a P/E ratio of -0.63 and a beta of 0.65. The firm’s 50-day moving average price is $3.67 and its 200-day moving average price is $3.64. Sintx Technologies has a 1-year low of $1.71 and a 1-year high of $7.36.

Sintx Technologies (NASDAQ:SINT) last issued its earnings results on Wednesday, November 12th. The company reported ($3.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.91). The firm had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.20 million. Sintx Technologies had a negative net margin of 775.12% and a negative return on equity of 218.25%.

Sintx Technologies Company Profile

Sintx Technologies, Inc (NASDAQ: SINT) is a medical materials company specializing in the development and manufacture of silicon nitride-based biomaterials for surgical and implantable medical devices. Its proprietary silicon nitride ceramic combines mechanical strength, biocompatibility and intrinsic antimicrobial properties, positioning it as an alternative to traditional metal and polymer implant materials. Sintx’s primary focus is on applications in spinal fusion, trauma fixation and dental implantology, where device performance and long-term biological response are critical.

The company’s core product offerings include silicon nitride powders for advanced implant fabrication and finished implantable components designed for interbody spinal fusion cages, spinal fixation hardware and trauma plates and screws.